Next Article in Journal
Loss of parla Function Results in Inactivity, Olfactory Impairment, and Dopamine Neuron Loss in Zebrafish
Next Article in Special Issue
Integrin α2β1 Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer
Previous Article in Journal
Zoom in on Antibody Aggregates: A Potential Pitfall in the Search of Rare EV Populations
Previous Article in Special Issue
Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 9
Issue 2
10.3390/biomedicines9020207
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis

by
Amreen Salwa
1,†,
Alessandra Ferraresi
1,†,
Menaka Chinthakindi
1,
Letizia Vallino
1,
Chiara Vidoni
1,
Danny N. Dhanasekaran
2 and
Ciro Isidoro
1,*
1
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale “A. Avogadro”, Via Solaroli 17, 28100 Novara, Italy
2
Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
*
Author to whom correspondence should be addressed.
†
These authors have equally contributed and each should be regarded as first author.
Biomedicines 2021, 9(2), 207; https://doi.org/10.3390/biomedicines9020207
Submission received: 23 December 2020 / Revised: 21 January 2021 / Accepted: 12 February 2021 / Published: 18 February 2021
(This article belongs to the Special Issue Role of Biomarkers and Targeted Therapy in the Management of Ovarian Cancer)
Browse Figures
Versions Notes

Abstract

:
Background: BRCA1, BECN1 and TP53 are three tumor suppressor genes located on chromosome 17 and frequently found deleted, silenced, or mutated in many cancers. These genes are involved in autophagy, apoptosis, and drug resistance in ovarian cancer. Haploinsufficiency or loss-of-function of either TP53, BRCA1 or BECN1 correlates with enhanced predisposition to cancer development and progression, and chemoresistance. Expectedly, the combined altered expression of these three tumor suppressor genes worsens the prognosis of ovarian cancer patients. However, whether such a genotypic pattern indeed affects the chemo-responsiveness to standard chemotherapy thus worsening patients’ survival has not been validated in a large cohort of ovarian cancer patients. Aim: We interrogated datasets from the TCGA database to analyze how the expression of these three tumor suppressor genes impacts on the clinical response to platinum-based chemotherapy thus affecting the survival of ovarian cancer patients. Results and conclusion: Compared to EOC with homozygous expression of BECN1 and BRCA1, tumors expressing low mRNA expression of these two tumor suppressor genes (either because of shallow (monoallelic) co-deletion or of promoter hypermethylation), showed higher sensitivity to platinum-based therapies and were associated with a better prognosis of ovarian cancer-bearing patients. This outcome was independent of TP53 status, though it was statistically more significant in the cohort of patients with mutated TP53. Thus, sensitivity to platinum therapy (and probably to other chemotherapeutics) correlates with low expression of a combination of critical tumor suppressor genes. Our study highlights the importance of thoroughly assessing the genetic lesions of the most frequently mutated genes to stratify the patients in view of a personalized therapy. More importantly, the present findings suggest that targeting the function of both BECN1 and BRCA1 could be a strategy to restore chemosensitivity in refractory tumors.

Graphical Abstract

1. Introduction

Ovarian cancer ranks as the eighth leading cause of cancer-related deaths among women, and a leading cause of death from gynecological cancer [1]. The majority (up to 90%) of ovarian cancers are epithelial ovarian cancers (EOC) [2]. Ovarian cancer remains one of the most lethal gynecologic malignancies with a 5 years of survival rate lower than 50%, due to the lack of effective diagnosis of the disease at early stage and the persistence of drug-resistance [3,4]. Currently, the standard of care for EOC patients includes primary cytoreductive surgery followed by a platinum-based chemotherapy, that is considered as first-line treatment. Drugs such as cisplatin, oxaliplatin and carboplatin exert an anti-tumor effect by inducing intra-strand and inter-strand cross-links in genomic DNA and are cell cycle-non-specific in action. Although many patients initially respond to the treatment, more than 75% of high grade serous ovarian cancer (HGSOC) patients develop drug resistance within one year and eventually relapse [5,6]. Understanding the gene signature underlying chemoresistance would help to design personalized therapeutic interventions in ovarian cancer patients.
Based on the genetic mutations and clinical features, EOC are classified in Type-I and Type-II [7]. Type-I tumors are indolent, low progressing with relative genomic stability. These tumors frequently present mutations in KRAS, BRAF, PTEN, PI3KCA and ERBB2 genes [7]. In contrast, Type-II tumors have an aggressive behavior, genomic instability, and present mutations in BRCA1, BRCA2 and TP53 genes [8].
Reportedly, the deletion or loss-of-function of single tumor suppressor genes associates with cancer progression and worse prognosis. However, conflicting data are present in the literature, which prompted us to undertake the present study.
TP53 tumor suppressor gene located on chromosome 17pl3 encodes a transcription factor for genes involved in the regulation of cell cycle, DNA repair, cell death and autophagy [9,10,11]. Mutations in TP53 have been reported in approximately 40–80% of EOC [12,13,14], more frequently in advanced stage III and IV, and this correlated with worse clinical outcome [15,16,17]. Yet, in the TCGA cohort it was found that ovarian cancers with wild-type TP53 were more chemoresistant and consequently associated with a poorer clinical outcome than those with mutated TP53 [18].
BRCA1 is one breast and ovarian cancer susceptibility gene that plays an important role in DNA damage repair and cell cycle regulation [19,20]. Germ-line mutation, somatic mutations, and methylation have been reported to alter BRCA1 expression [21,22]. In advanced stage HGSOC, patients with germline BRCA1/2 mutations have better prognosis [23,24,25]. BRCA2 mutation, but not BRCA1 mutation, was associated with significantly improved overall survival rate [26]. BRCA1 negatively affects pro-survival autophagy in ovarian cancer cells [27,28].
BECN1, the first identified mammalian autophagy gene [29,30], maps on chromosome 17q21 in a region of around 150 kb centromeric to BRCA1 [31]. Due to their close proximity, these two tumor suppressor genes are commonly co-deleted in breast and ovarian cancers and are expressed at reduced levels in these tumors [29,32]. BECLIN 1 regulates apoptosis by recruiting the anti-apoptotic protein of BCL-2 family (BCL-2 and BCL-XL) to the BH3 domain [33,34]. High expression of BECLIN 1 along with low expression of BCL-2 associates with good prognosis in non-Hodgkin lymphomas [35] and, conversely, low expression of BECLIN 1 with high expression of BCL-xL associated with poor prognosis in hepatocellular carcinomas [36]. However, in nasopharyngeal carcinomas high level of BECLIN 1 along with HIF-1α predicts poor prognosis [37]. BECN1 expression was found higher in benign and borderline ovarian tumors than in malignant EOC, suggesting that its decreased expression could favor tumorigenesis [38]. Accordingly, monoallelic loss of BECN1 drives chromosome instability (leading to copy-number variation), increases migration, and promotes early ovarian tumors [39]. In an advanced stage of ovarian cancer, low expression of BECN1 and high level of BCL-2 (anti-apoptotic protein) was associated with poor prognosis [40,41]. Type I EOC was found to express higher levels of BECN1 and LC3 (the latter is an autophagy marker) compared to the aggressive Type II, and this was associated with chemo-responsiveness and better prognosis [42]. On the other hand, increased expression of BECN1 was found to be associated with aggressive endometrioid adenocarcinomas and correlated with poor 5-years overall survival [43].
Thus, when considered individually, the altered expression of either of these three tumor suppressor genes appears associated with chemoresistance and poor clinical outcome or alternatively with chemosensitivity and good prognosis in ovarian cancer. Expectedly, the combined deletion or mutation of several tumor suppressor genes aggravates cancer progression and chemoresistance, thus worsening the prognosis. However, this assumption has not been validated yet for BECN1, BRCA1 and TP53 in EOC, three tumor suppressor genes that control autophagy, apoptosis, and DNA repair, and influence cancer cell fate in response to chemotherapy.
Here, we have interrogated datasets from the TCGA database publicly available to better understand the role of BECN1 and BRCA1 deficiency in progression and chemo-responsiveness to platinum-based therapy in wild-type and mutated TP53 ovarian cancers. Surprisingly, we found that the combined low/dysfunctional expression of these three main tumor suppressor genes in EOC associates with better prognosis, and this correlates with high responsiveness to platinum therapy.
This study confirms that genotyping the cancer for certain critical oncogenes or tumor suppressor genes is mandatory for predicting the responsivity to chemotherapy, a step toward personalized treatments. Further, our study suggests that targeting the expression/function of both BRCA1 and BECN1 can improve the cytotoxic efficacy of platinum-based drugs.

2. Methods

2.1. Genetic Profiling of Ovarian Serous Cystadenocarcinoma

Data of 316 patients, diagnosed for ovarian serous cystadenocarcinoma, were retrieved from The Cancer Genome Atlas (TCGA) (https://portal.gdc.cancer.gov/, accessed on 27 October 2020) [14]. The patients’ characteristics have been reported in Supplementary Table S1, and the selection and exclusion criteria of the study cohort is depicted in the flow chart shown in Supplementary Figure S1. All the patients underwent primary cytoreductive surgery, followed by an adjuvant platinum-based chemotherapy as a first-line treatment. Eligibility criteria for the study were (1) histologically verified diagnosis of high-grade serous ovarian adenocarcinomas; (2) lack of neo-adjuvant therapy; (3) platinum sensitivity (the time from adjuvant platinum-based treatment to cancer relapse (platinum-free interval (PFI), was >6 months).
In TCGA ovarian cancer mRNA gene expression, copy number variation (CNV), TP53-mutation status, DNA methylation and clinical data (FIGO stage, grade, overall survival and disease-free status and platinum sensitivity/resistance) were downloaded from the cBioportal.org.
TCGA gene expression profile was measured using the Illumina HiSeq 2000 RNA Sequencing platform (Illumina Inc., 9885 Towne Centre Drive, San Diego, CA 92121, USA). RSEM (RNA-Seq by Expectation-Maximization) normalized count was used as gene level expression estimates. TCGA copy number profile was measured using genome-wide SNP6 array. Gene-level somatic copy number alterations were estimated using the GISTIC 2.0 [44] method which summarized the copy number of each gene into −2, −1, 0, 1, 2, representing the homozygous/deep deletion (−2), heterozygous/shallow deletion (−1), diploid normal copy (0), low-level amplification (+1), or high-level amplification (+2), respectively (Supplementary Table S1). TP53-mutation status was also obtained from the TCGA data portal (Supplementary Table S1). Lastly, TCGA tumor grade and stage information were manually extracted from the pathologic reports provided by the cBioportal.

2.2. Statistical Analysis

The analysis focused on 316 ovarian serous cystadenocarcinoma in TCGA dataset. For statistical significance, the analysis was performed on tumors with shallow deletion and diploid CNV that were the most represented ones.
BECN1 and BRCA1 were grouped based on (i) the CNV (copy number variation) and (ii) the level of mRNA expression in ovarian cancer patients. The latter was sub-classified based on the level of Z-score values as high, medium and low, respectively. Low versus high mRNA expression was defined relative to the median expression level of all patients in the form of a box plot and were used to investigate the relationship between dichotomized BECN1 and BRCA1 expression. To reduce the potential bias from dichotomization, the mRNA expression of BECN1 and BRCA1 were compared based on CNV, TP53 mutation and expression-based groups using t-test (Welch Two Sample t-test) by R. All cut-off values were set before the analysis, and all the tests were two-tailed.
All statistical analyses were performed by R (3.6.1 version, The R Foundation for Statistical Computing, Vienna, Austria) and SAS software (9.4. version, SAS Institute Inc., Cary, NC, USA) using SAS/STATs procedures for BECN1 and BRCA1 in different sample sized groups.
Survival analysis was performed using SAS for the following: TP53 mutation, CNV and mRNA expression level-based groups of BECN1 and BRCA1. Survival curves of these three groups were estimated by the Kaplan–Meier plots and compared using the Cox regression model assuming an ordered trend for the three groups as described previously. The log-rank test has been used to determine the statistical significance. The p-value < 0.05 was considered to be significant.

3. Results

3.1. Clinical Characteristics of the Patient Cohort

The Ovarian Cancer Data Set (Consortium TCGA, Nature 2011) available in TCGA database (www.cBioportal.org, accessed on 27 October 2020) consists of 316 High Grade Serous Ovarian Cancer patients (HGSOC). The cohort of patients with HGSOC comprised cases with N/A (1) II (14), III (248), and IV (53) FIGO stages. The tumor grade was determined as G2 in 28 cases, G3 in 281 cases, and undetermined for other cases. All patients underwent primary cytoreductive surgery, followed by first-line platinum-based chemotherapy. All patients experienced a complete or a partial response post-adjuvant therapy with platinum-free interval (PFI) >6 months. Patients reporting data on TP53 (mutated and wild type), BECN1 and BRCA1, were categorized based on putative changes in DNA copies (CNV). Diploid, shallow deletion, amplification and gain of BECN1 and BRCA1 genes and clinical data are detailed in Supplementary Table S1

3.2. Oncoprint of Somatic Mutations in Ovarian Cancer

As represented in Figure 1, in a total of 316 ovarian cancers, BECN1 has been observed amplified in one patient and bearing a missense mutation in another patient (0.6%); BRCA1 mutated cases were observed in 38 patients (12%), and mutated TP53 was reported in as many as 303 patients (96%). As for the type of genetic alteration, missense and truncating mutations were the most frequent ones. Figure 1 also reports the level of mRNA expression of the three tumor suppressor genes. It is evident that with a few exceptions the large majority of the EOC analyzed express low or very low level of mRNA for the three tumor suppressor genes, especially in the case of BECN1, while abnormally high level of BECN1 or BRCA1 mRNA is observed in only one case, respectively, that associates with gene amplification.

3.3. Patients with Mutated TP53 Have Significantly Better Survival Than Those with Wild Type TP53

First, we focused on TP53 status. Patients with mutated TP53 (n = 303) showed significantly better overall and disease-free survival with significant values p = 0.0489 and p = 0.0221 respectively, than those with wild type TP53 (n = 13 and n = 11, respectively) (Figure 2A,B). The median overall survival among the patients with wild type TP53 was 27 months, while it was about 50 months in mutated TP53 patients. Intriguingly, the group of tumors with mutated TP53 presented lower expression of BECN1 (p = 0.1427) and of BRCA1 (p = 0.0329) than the group of tumors with wild type TP53 (Figure 2C,D). As these findings were unexpected, and somehow counterintuitive, we further interrogated the data base in search of a possible explanation for the poor prognosis in the wild-type TP53 group (possibly due to additional oncogenic mutations) and for the good prognosis in mutated TP53 group (possibly related to therapy responsiveness).

3.4. Mutational Profiles of High-Grade Ovarian Serous Cystadenocarcinoma with Wild Type TP53

In the 13 tumor samples with wild type TP53 from TCGA data (validated for somatic mutation status), we identified 490 genes that were mutated (Supplementary Table S2). This list of genes was analyzed by using DAVID bioinformatics functional annotation tool (https://david.ncifcrf.gov/summary.jsp, accessed on 22 September 2020) to obtain Gene Ontology (GO) biological processes. We found 267 genes involved in pathogenesis of cancer, which could have contributed to ovarian carcinogenesis despite the normally functioning of TP53 (Supplementary Figure S2).

3.5. BECN1 and BRCA1 Deletions Correlate with High Tumor Stage and Grade

Most patients were diagnosed with tumors at stage III and IV (78.4% and 16.8% respectively), and of grade G3 (88.9%). As shown in Figure 3, shallow co-deletion of BECN1 and BRCA1 occurs in >83% of the tumors at stage IIIc and IV and of grade 3.

3.6. Correlation of BECN1 and BRCA1 Co-deletion

In the 316 ovarian cancers in TCGA, BECN1 and BRCA1 were shallow (monoallelic) deleted in 242 (76.6%) and 240 (76%) cases, respectively (Supplementary Table S1). A co-occurrence analysis of CNV revealed that the two events were highly correlated (Supplementary Table S3), which was expected given the close proximity of these two genes on chromosome 17q21. Out of 316 cases, CNV was identical for both BECN1 and BRCA1 in 313 cases (50 diploid, 240 shallow deletion, 23 amplification), while 2 cases with BECN1 shallow deletion were associated one with amplification and one with deep deletion of BRCA1, and one case diploid for BRCA1 was amplified for BECN1 (Supplementary Table S3). It is to be noted that no one tumor had a deep (homozygous) co-deletion of both BECN1 and BRCA1, and only one tumor had a deep deletion of BRCA1 associated with shallow deletion of BECN1.

3.7. Patients with Shallow Deletion of BECN1 and BRCA1 Have Better Prognosis

To determine the prognostic role of BECN1 and BRCA1, we analyzed the survival of patients bearing a tumor with consistent CNV of the tumor suppressor genes, i.e., with both shallow deletion (240 cases) or diploid (50 cases) status (see Supplementary Table S3). Overall survival and disease-free survival data were not available for 1 (diploid) case and for 51 (16 diploid and 35 shallow deleted) cases, respectively.
Based on BECN1 and BRCA1 CNV (diploid versus shallow deletion), it is apparent that patients bearing an ovarian cancer with shallow deletion of the two tumor suppressor genes have a significant better prognosis, i.e., overall and disease-free survival (p = 0.0105 and p = 0.0364) than the patients bearing a cancer with diploid CNV, independently of the TP53 status (Figure 4A,B). We confirmed that shallow deletion corresponded to lower expression of the gene. As shown in Figure 4C,D, the average level of mRNA expression of BECN1 and BRCA1 in the 240 tumors with shallow deletion CNV was lower than the corresponding level in the 50 tumors with diploid CNV, indicating that the monoallelic loss of the tumor suppressor gene reflected in lower mRNA expression. Notably, the relationship between copy number loss and mRNA expression was more significant for BECN1 than for BRCA1 in this dataset (p-value = 5.149 × 10−15 and p-value = 0.000798, respectively).

3.8. Patients Bearing a Tumor with Shallow Co-deletion of BECN1 and BRCA1 along with Mutated TP53 Have Better Prognosis

TP53 was mutated in 43 (86%) of 50 cases diploid for both BECN1 and BRCA1, and in 236 (98%) of the 240 cases shallow deleted for BECN1 and BRCA1. The low number (n = 11; 7 CNV diploid + 4 CNV shallow for BECN1 and BRCA1) of patients with wild type TP53 does not allow to draw conclusion statistically significant. Since TP53 was mutated in the vast majority of the tumors, we asked about its contribution in the prognostic value of BECN1 and BRCA1.
As expected, overall survival (p = 0.0088) and disease-free survival (p = 0.0575) were higher in the patients bearing a tumor with shallow deletion of both BECN1 and BRCA1 compared to those bearing a tumor with a diploid CNV of the two tumor suppressor genes (Figure 5A,B). Notably, the p-value of the overall survival of the patients bearing cancer with shallow CNV of BECN1 and BRCA1 was more significant in TP53 mutated than in the whole cohort (p = 0.0088 versus p = 0.0105) (Figure 4A and Figure 5A). It was also confirmed that copy number loss (shallow deletion) of BECN1 and BRCA1 corresponded to lower level of the respective mRNA (Figure 5C,D; p = 1.203 × 10−13 and p = 0.0009108, respectively).

3.9. Low Level of BECN1 and BRCA1 mRNA in TP53-mutated Ovarian Cancer Predicts Better Patient Prognosis

Previous data showed that shallow CNV of BECN1 and BRCA1 correlates with low level of mRNA in the tumor and with better prognosis of the patients. However, gene expression rather than gene copy number defines the phenotype. Low gene expression depends also on epigenetic silencing, besides gene copy number loss. One important epigenetic modification is the DNA methylation (particularly, the 5-methylcytosine within CpG isles) in the gene promoter, which can be detected with the HumanMethylation27 (HM27k) array [45]. We found that decreased expression of BECN1 and BRCA1 in ovarian cancers was significantly associated with high DNA methylation of these genes (Supplementary Figure S3).
We have classified the tumors for the expression level of BECN1 and BRCA1 mRNA in three distinct groups (high, medium, and low) according to the z-score values and the methylation status, as indicated in Supplementary Figure S3. Next, we looked at the prognosis in patients bearing a TP53-mutated ovarian cancer according to the high or medium or low level of mRNA expression of BECN1 and BRCA1 (Figure 6). Patients with the medium or low level of BECN1 and BRCA1 expression (corresponding to a high methylation profile) showed a significant better prognosis (i.e., long overall survival and disease-free survival) than the patients bearing tumors with high level of BECN1 and BRCA1 mRNAs (Figure 6).
We classified the patients with medium and low level of mRNA expression of the two genes as low expressors and found that, compared to this group of patients, the group of high expressors showed poor prognosis (Supplementary Figure S4).
Next, we attempted to discriminate the individual contribution of BECN1 and BRCA1 expression to the prognosis. To this end, we grouped the cases with medium and low expression of each single gene and analyzed the prognostic value of the combinatorial groups of tumors based on the respective level of mRNA expression of BECN1 and BRCA1 as follow: H/H (High BECN1/High BRCA1), H/L (High BECN1/Low BRCA1), L/H (Low BECN1/High BRCA1), and L/L (Low BECN1/Low BRCA1). From this analysis it appears evident that tumors with high mRNA expression of both genes (H/H) have the worse prognosis, while those with low mRNA expression of both genes (L/L) have the best prognosis (Figure 7). On the other hand, the individual lower expression of either BECN1 or BRCA1 (the combination L/H or H/L) does not confer significant improvement of the clinical outcome, suggesting that it is the concurrent loss of function of both the tumor suppressor genes that determines the good prognosis.

3.10. BECN1 and BRCA1 Deficiency Correlates with Platinum Sensitivity

Platinum resistant patients show disease progression within six months of primary therapy, while platinum sensitive patients show relapse or disease progression six months after the end of treatment. From a total of thirteen wild type TP53 patients, only three were found chemo-sensitive and eleven were deceased. Of the latter, five were resistant to the standard platinum chemotherapy and have recurred the disease in less than 6 months. Unfortunately, data regarding other patients were not available (N/A) (Supplementary Table S4). Taken together, above data indicate that the patients bearing a tumor with wild type TP53 experience bad prognosis, and this associates with high expression of BECN1 and BRCA1 mRNA and with platinum-resistance, while the opposite is observed for the patients bearing a tumor with mutated TP53 that associated with decreased mRNA levels of BECN1 and BRCA1 (Figure 1). To be noted, of 213 EOC with mutant TP53, 125 (58.69%) are sensitive, 57 (26.76%) are late resistance and 31 (14.55%) are too-early resistant (for 90 patients’ data were not available (N/A)). Therefore, we asked about the response toward the platinum-based chemotherapy in the TP53- mutated tumors with respect to the combined BECN1 and BRCA1 copy number variation (279 cases). To be noted, for 82 of these patients (approx. 30%; 62 with shallow deletion and 20 diploid) no information on the platinum sensitivity in relation to BECN1 and BRCA1 CNV status was available. Of the patients bearing a tumor with BECN1 and BRCA1 shallow deletion (174), 105 (60.4%) of patients were sensitive, 47 (27%) were resistant and 22 (12.6%) developed early resistance. In contrast, of 23 patients bearing a tumor with diploid CNV of BECN1 and BRCA1 only 11 (48%) were sensitive, 6 (26%) developed resistance and 6 (26%) developed an early resistance, as shown in Figure 8.
Finally, platinum-responsive status (116 patients) was correlated to low, medium and high expression of BECN1 and BRCA1. Patients with low levels of BECN1 (66 patients) were significantly more sensitive compared to medium BECN1 expressors (40 patients), while only 10 patients with high BECN1 expression were sensitive to the therapy. A similar trend was observed for BRCA1 expression. Both low (58 patients) and medium (46 patients) BRCA1 mRNA expressors were sensitive to platinum treatment, whereas only 12 patients with high BRCA1 expression manifest a great response to chemotherapy.
Because of the small number of patients, we could not demonstrate a significant association between the high expression of BECN1 and BRCA1 genes and chemosensitivity, however the collected data indicate that high expression of both these tumor suppressor genes results in chemotherapy resistance while medium-low expression is significantly associated with platinum-sensitivity.

4. Discussion

The stratification of HGSOC patients in poor and good responders to the platinum-based first-line therapy is crucial for implementation of personalized ovarian cancer treatment, and for this it is important to genotyping the tumor for critical risk genes [46,47]. Dysfunction of tumor suppressor genes (low expression or loss-of-function mutations) has been associated with tumor development and progression, and with poor clinical outcome. However, the contribution of one single risk gene is influenced by the concurrent mutation of other risk genes involved in the same or intersected processes [46], and this is likely to affect the final outcome.
Here, we focused on the concurrent contribution of three main tumor suppressor genes, namely TP53, BECN1 and BRCA1, in determining the clinical response to therapy and clinical outcome in ovarian cancer patients. These genes were chosen because of their primary role in the control of the pathways that govern cell survival, cell death and DNA repair, and ultimately the response to chemotherapeutic injury. These three tumor suppressor genes locate on chromosome 17, and are frequently found co-mutated [32,48]. Consistently, in the 316 ovarian cancers present in the TCGA, as many as 236 were showing deletion or mutation in these three tumor suppressor genes.
In our first analysis we found that 13 patients bearing a wild type TP53 HGSOC had worse prognosis associated with chemoresistance compared to the 303 patients bearing a mutated TP53 tumor. This is a confirmation of the previous study by Wong et al (2013) on the same database [18]. Note that more recently the number of wild type TP53 cases has been revised from 15 to 13 [13]. Compared to that study where 88 genes involved in carcinogenesis were found mutated [18], we have updated the list of the mutated genes (260 out of 490) that could have contributed to the bad prognosis in the patients with wild type TP53 (Supplementary Table S2). These genes appear mainly involved in cell receptor signaling, cell morphogenesis and cell adhesion and migration (Supplementary Figure S2).
Most importantly, and of relevance for our aim, we found that tumors with wild type TP53 had a tendency to express higher level of BRCA1 (statistically significant) and of BECN1 (though not significant) than the tumors with mutated TP53. Low mRNA expression of BECN1 and BRCA1 was confirmed in the subset of tumors with mutated TP53, and it was significantly correlated with platinum sensitivity and good prognosis. We found that low mRNA expression of both genes arose from monoallelic (shallow) deletion as well as from promoter hyper-methylation. Monoallelic co-deletion of BECN1 and BRCA1 has been reported in 40-75% of sporadic ovarian cancers [31]. BECN1 is a haploinsufficient tumor suppressor gene, since it opposes tumorigenesis when over-expressed [29] but favors tumorigenesis when present in single copy (30). BRCA1 also is bona fide a haploinsufficient tumor suppressor gene, though its heterozygous expression does not promote spontaneous tumors [49]. We observed that the vast majority of the tumors at stage III and IV and of grade 3 were bearing shallow deletions (i.e., expressing one single allele) of both BECN1 and BRCA1, further indicating that the low expression of these tumor suppressor genes associates with ovarian cancer progression. Accordingly, the expression of BECN1 was found significantly higher in benign and borderline ovarian cancer than in aggressive ovarian cancer, and inversely correlated with the increasing FIGO stage and histologic grade of malignant EOC [38]. Yet, another study found that the expression of BECLIN 1 protein was stronger in ovarian carcinoma than that in normal ovary and benign tumor [50]. It was also found that EOC expressed higher level of BECLIN 1 along with lower level of BRCA1 in EOC than in benign epithelial ovarian tumor tissues [51]. Our results are coherent with previous findings showing cisplatin sensitivity in ovarian cancers with low expression of BRCA1 [51,52,53]. Interestingly, low expression of BECLIN 1 and of BRCA1 proteins identified platinum-responsive patients, and this was associated with impaired autophagy [51]. Consistently, BRCA1 deficient ovarian cancer cells were highly dependent on BECLIN 1-dependent autophagy for survival, and rapidly underwent cell death upon autophagy disruption [27,28]. In summary, the present study demonstrates that the concurrent low expression of BECN1 and BRCA1 is sufficient to make ovarian cancer cells more sensitive to chemotherapeutics. In principle, it might seem counterintuitive that low expression of two tumor suppressor genes favors a good clinical outcome. This is particularly surprising since both BECN1 and BRCA1 were found expressed at very low level in the tumors with more aggressive phenotype (stage and grade). However, what finally determines if the cell will survive or succumb to a cytotoxic stress much depends on the combination of the risk genes that loose or gain in function and how this combination impact on the pathways controlling autophagy, cell death, DNA repair and cell metabolism. BRCA1 deficiency was shown to promote BECLIN 1-dependent autophagy that protected ovarian cancer cells (and benign ovarian epithelial cells) from toxic metabolic stress [27]. Thus, the loss of BECN1 combined with BRCA1 deficiency probably compromises autophagy-mediated protection from platinum-toxicity. In this respect, it is worth noting that no one tumor had a deep (homozygous) co-deletion of both BECN1 and BRCA1, which is consistent with the fact that complete loss of these tumor suppressor genes is incompatible with cell survival [30,54]. As a matter of fact, our analysis shows that the down-regulation of BECN1 and BRCA1 expression could restore the ability of ovarian cancer cells to respond to platinum-based therapy, even in wild-type TP53 patients. Translating into clinics the above considerations, one could envisage a therapeutic strategy for knocking-down both BRCA1 and BECN1 to drive ovarian cancer cell death. In this respect, phytochemicals acting as epigenetic modulators could represent a source of valid adjuvant therapeutics [55,56].

5. Conclusions

We have interrogated datasets from the TCGA database to define how the genetic and epigenetic alterations of BECN1, BRCA1 and TP53, three tumor suppressor genes that control autophagy, apoptosis, and DNA repair, contribute to the chemo-responsiveness to platinum-based therapy and the prognosis in ovarian cancers. Our analysis demonstrates that the concurrent low expression of BECN1 and BRCA1 is sufficient to make ovarian cancer cells more sensitive to chemotherapeutics. The present study confirms the importance of genotyping the cancer for critical risk genes involved in chemoresistance for designing a personalized therapy.

Supplementary Materials

The following are available online at https://www.mdpi.com/2227-9059/9/2/207/s1. Supplementary Figure S1: Flow diagrams depicting the selection of the study population; Supplementary Figure S2: Biological processes associated with mutated genes in 13 patients bearing an ovarian cancer with wild type TP53; Supplementary Figure S3: Correlation of BECN1 and BRCA1 mRNA expression with methylation values of their respective gene; Supplementary Figure S4: High expression of BECN1 and BRCA1 gives poor overall and disease-free survival compared to low plus medium BECN1 and BRCA1 mRNA expression in TP53-mutated patients; Supplementary Table S1: Characteristics of High Grade Serous Ovarian Cancer patients in TCGA database; Supplementary Table S2: Gene mutations in TCGA ovarian samples with wild type TP53; Supplementary Table S3: Correlation between CNV of BECN1 and BRCA1; Supplementary Table S4: Clinical outcome of patients bearing the ovarian tumor with wild type TP53.

Author Contributions

A.S. and C.I., conceptualization; A.S., M.C. and L.V., interrogation of TCGA and Kaplan-Meier database, statistical analysis, Kaplan–Meier plots, figures, bibliography search; A.S., A.F. and C.V., data interpretation, tables, manuscript draft, statistical analysis; D.N.D. and C.I., interpretation of data, paper finalization. All authors have read and agreed to the published version of the manuscript.

Funding

A.S. was supported with a short-term fellowship granted by Consorzio InterUniversitario per le Biotecnologie CIB (Trieste, Italy). A.F. is recipient of a post-doctoral fellowship “Paolina Troiano” (id. 24094) granted by Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan, Italy). L.V. is a PhD student recipient of a fellowship granted by the Italian Ministry of Education, University and Research (MIUR, Rome, Italy) with the contribution of Associazione per la Ricerca Medica Ippocrate-Rhazi (ARM-IR, Novara, Italy). C.V. was supported with a fellowship from Associazione per la Ricerca Medica Ippocrate-Rhazi (ARM-IR, Novara, Italy). C.V. was supported with a post-doctoral fellowship from Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (id. 1412) granted by Fondazione Cassa di Risparmio di Torino (CRT, Torino, Italy).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Cabasag, C.J.; Butler, J.; Arnold, M.; Rutherford, M.; Bardot, A.; Ferlay, J.; Morgan, E.; Møller, B.; Gavin, A.; Norell, C.H.; et al. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study. Gynecol. Oncol. 2020, 157, 234–244. [Google Scholar] [CrossRef]
  2. Kurman, R.J.; Shih, I. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am. J. Surg. Pathol. 2010, 34, 433–443. [Google Scholar] [CrossRef] [Green Version]
  3. Coleman, R.L.; Monk, B.J.; Sood, A.K.; Herzog, T.J. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat. Rev. Clin. Oncol. 2013, 10, 211–224. [Google Scholar] [CrossRef] [Green Version]
  4. Vaughan, S.; Coward, J.I.; Bast, R.C., Jr.; Berchuck, A.; Berek, J.S.; Brenton, J.D.; Coukos, G.; Crum, C.C.; Drapkin, R.; Etemadmoghadam, D.; et al. Rethinking ovarian cancer: Recommendations for improving outcomes. Nat. Rev. Cancer. 2011, 11, 719–725. [Google Scholar] [CrossRef] [Green Version]
  5. Chang, S.J.; Bristow, R.E.; Chi, D.S.; Cliby, W.A. Role of aggressive surgical cytoreduction in advanced ovarian cancer. J. Gynecol. Oncol. 2015, 26, 336–342. [Google Scholar] [CrossRef] [Green Version]
  6. Coward, J.I.; Middleton, K.; Murphy, F. New perspectives on targeted therapy in ovarian cancer. Int. J. Womens Health 2015, 7, 189–203. [Google Scholar] [CrossRef] [Green Version]
  7. Romero, I.; Bast, R.C., Jr. Minireview: Human ovarian cancer: Biology, current management, and paths to personalizing therapy. Endocrinology 2012, 153, 1593–1602. [Google Scholar] [CrossRef] [Green Version]
  8. Kurman, R.J.; Shih, I.-M. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Am. J. Pathol. 2016, 186, 733–747. [Google Scholar] [CrossRef] [Green Version]
  9. Aubrey, B.J.; Strasser, A.; Kelly, G.L. Tumor-Suppressor Functions of the TP53 Pathway. Cold Spring Harb. Perspect Med. 2016, 6, a026062. [Google Scholar] [CrossRef] [Green Version]
  10. Li, T.; Kon, N.; Jiang, L.; Tan, M.; Ludwig, T.; Zhao, Y.; Baer, R.; Gu, W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012, 149, 1269–1283. [Google Scholar] [CrossRef] [Green Version]
  11. Hu, W.; Chen, S.; Thorne, R.F.; Wu, M. TP53, TP53 Target Genes (DRAM, TIGAR), and Autophagy. Adv. Exp. Med. Biol. 2019, 1206, 127–149. [Google Scholar] [CrossRef]
  12. Zhang, Y.; Cao, L.; Nguyen, D.; Lu, H. TP53 mutations in epithelial ovarian cancer. Transl. Cancer Res. 2016, 5, 650–663. [Google Scholar] [CrossRef]
  13. Vang, R.; Levine, D.A.; Soslow, R.A.; Zaloudek, C.; Shih, I.-M.; Kurman, R.J. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Int. J. Gynecol. Pathol. 2016, 35, 48–55. [Google Scholar] [CrossRef] [Green Version]
  14. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474, 609–615. [Google Scholar] [CrossRef]
  15. Reles, A.; Wen, W.H.; Schmider, A.; Gee, C.; Runnebaum, I.B.; Kilian, U.; Jones, L.A.; El-Naggar, A.; Minguillon, C.; Schönborn, I.; et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res. 2001, 7, 2984–2997. [Google Scholar]
  16. Righetti, S.C.; Della Torre, G.; Pilotti, S.; Ménard, S.; Ottone, F.; Colnaghi, M.I.; Pierotti, M.A.; Lavarino, C.; Cornarotti, M.; Oriana, S.; et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 1996, 56, 689–693. [Google Scholar]
  17. Sood, A.K.; Sorosky, J.I.; Dolan, M.; Anderson, B.; Buller, R.E. Distant metastases in ovarian cancer: Association with p53 mutations. Clin. Cancer Res. 1999, 5, 2485–2490. [Google Scholar]
  18. Wong, K.K.; Izaguirre, D.I.; Kwan, S.Y.; King, E.R.; Deavers, M.T.; Sood, A.K.; Mok, S.C.; Gershenson, D.M. Poor survival with wild-type TP53 ovarian cancer? Gynecol. Oncol. 2013, 130, 565–569. [Google Scholar] [CrossRef] [Green Version]
  19. Song, C.V.; Teo, S.H.; Taib, N.A.; Yip, C.H. Surgery for BRCA, TP53 and PALB2: A literature review. Ecancermedicalscience 2018, 12, 863. [Google Scholar] [CrossRef] [Green Version]
  20. Sobhian, B.; Shao, G.; Lilli, D.R.; Culhane, A.C.; Moreau, L.A.; Xia, B.; Livingston, D.M.; Greenberg, R.A. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007, 316, 1198–1202. [Google Scholar] [CrossRef] [Green Version]
  21. Russell, P.A.; Pharoah, P.D.; De Foy, K.; Ramus, S.J.; Symmonds, I.; Wilson, A.; Scott, I.; Ponder, B.A.; Gayther, S.A. Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. Int. J. Cancer 2000, 87, 317–321. [Google Scholar] [CrossRef]
  22. Dhillon, K.K.; Swisher, E.M.; Taniguchi, T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci. 2011, 102, 663–669. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Chetrit, A.; Hirsh-Yechezkel, G.; Ben-David, Y.; Lubin, F.; Friedman, E.; Sadetzki, S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer. J. Clin. Oncol. 2008, 26, 20–25. [Google Scholar] [CrossRef]
  24. Alsop, K.; Fereday, S.; Meldrum, C.; deFazio, A.; Emmanuel, C.; George, J.; Dobrovic, A.; Birrer, M.J.; Webb, P.M.; Stewart, C.; et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 2012, 30, 2654–2663. [Google Scholar] [CrossRef] [Green Version]
  25. Tan, D.S.; Rothermundt, C.; Thomas, K.; Bancroft, E.; Eeles, R.; Shanley, S.; Ardern-Jones, A.; Norman, A.; Kaye, S.B.; Gore, M.E. "BRCAness" syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin. Oncol. 2008, 26, 5530–5536. [Google Scholar] [CrossRef]
  26. Yang, D.; Khan, S.; Sun, Y.; Hess, K.; Shmulevich, I.; Sood, A.K.; Zhang, W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011, 306, 1557–1565. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Tang, M.K.; Kwong, A.; Tam, K.F.; Cheung, A.N.; Ngan, H.Y.; Xia, W.; Wong, A.S. BRCA1 deficiency induces protective autophagy to mitigate stress and provides a mechanism for BRCA1 haploinsufficiency in tumorigenesis. Cancer Lett. 2014, 346, 139–147. [Google Scholar] [CrossRef] [PubMed]
  28. You, Y.; Bi, F.F.; Jiang, Y.; Xu, Y.T.; An, Y.Y.; Li, D.; Yang, Q. BRCA1 affects the resistance and stemness of SKOV3-derived ovarian cancer stem cells by regulating autophagy. Cancer Med. 2019, 8, 656–668. [Google Scholar] [CrossRef]
  29. Liang, X.H.; Jackson, S.; Seaman, M.; Brown, K.; Kempkes, B.; Hibshoosh, H.; Levine, B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999, 402, 672–676. [Google Scholar] [CrossRef]
  30. Qu, X.; Yu, J.; Bhagat, G.; Furuya, N.; Hibshoosh, H.; Troxel, A.; Rosen, J.; Eskelinen, E.L.; Mizushima, N.; Ohsumi, Y.; et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J. Clin. Invest. 2003, 112, 1809–1820. [Google Scholar] [CrossRef] [Green Version]
  31. Aita, V.M.; Liang, X.H.; Murty, V.V.; Pincus, D.L.; Yu, W.; Cayanis, E.; Kalachikov, S.; Gilliam, T.C.; Levine, B. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 1999, 59, 59–65. [Google Scholar] [CrossRef]
  32. Laddha, S.V.; Ganesan, S.; Chan, C.S.; White, E. Mutational landscape of the essential autophagy gene BECN1 in human cancers. Mol. Cancer Res. 2014, 12, 485–490. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Wang, W.; Fan, H.; Li, X.; Wu, G.; Zhao, W.; Zhang, G.; Zhao, G.; Li, L. Beclin 1 promotes apoptosis and decreases invasion by upregulating the expression of ECRG4 in A549 human lung adenocarcinoma cells. Mol. Med. Rep. 2016, 14, 355–360. [Google Scholar] [CrossRef] [Green Version]
  34. Ciechomska, I.A.; Goemans, G.C.; Skepper, J.N.; Tolkovsky, A.M. Bcl-2 complexed with Beclin-1 maintains full anti-apoptotic function. Oncogene 2009, 28, 2128–2141. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Nicotra, G.; Mercalli, F.; Peracchio, C.; Castino, R.; Follo, C.; Valente, G.; Isidoro, C. Autophagy-active beclin-1 correlates with favourable clinical outcome in non-Hodgkin lymphomas. Mod. Pathol. 2010, 23, 937–950. [Google Scholar] [CrossRef]
  36. Shi, Y.H.; Ding, Z.B.; Zhou, J.; Qiu, S.J.; Fan, J. Prognostic significance of Beclin 1-dependent apoptotic activity in hepatocellular carcinoma. Autophagy 2009, 5, 380–382. [Google Scholar] [CrossRef] [Green Version]
  37. Wan, X.B.; Fan, X.J.; Chen, M.Y.; Xiang, J.; Huang, P.Y.; Guo, L.; Wu, X.Y.; Xu, J.; Long, Z.J.; Zhao, Y.; et al. Elevated Beclin 1 expression is correlated with HIF-1alpha in predicting poor prognosis of nasopharyngeal carcinoma. Autophagy 2010, 6, 395–404. [Google Scholar] [CrossRef] [Green Version]
  38. Shen, Y.; Li, D.D.; Wang, L.L.; Deng, R.; Zhu, X.F. Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer. Autophagy 2008, 4, 1067–1068. [Google Scholar] [CrossRef] [Green Version]
  39. Delaney, J.R.; Patel, C.B.; Bapat, J.; Jones, C.M.; Ramos-Zapatero, M.; Ortell, K.K.; Tanios, R.; Haghighiabyaneh, M.; Axelrod, J.; DeStefano, J.W.; et al. Autophagy gene haploinsufficiency drives chromosome instability, increases migration, and promotes early ovarian tumors. PLoS Genet. 2020, 16, e1008558. [Google Scholar] [CrossRef]
  40. Lin, H.X.; Qiu, H.J.; Zeng, F.; Rao, H.L.; Yang, G.F.; Kung, H.F.; Zhu, X.F.; Zeng, Y.X.; Cai, M.Y.; Xie, D. Decreased expression of Beclin 1 correlates closely with Bcl-xL expression and poor prognosis of ovarian carcinoma. PLoS ONE 2013, 8, e60516. [Google Scholar] [CrossRef] [PubMed]
  41. Cai, M.; Hu, Z.; Liu, J.; Gao, J.; Liu, C.; Liu, D.; Tan, M.; Zhang, D.; Lin, B. Beclin 1 expression in ovarian tissues and its effects on ovarian cancer prognosis. Int. J. Mol. Sci. 2014, 15, 5292–5303. [Google Scholar] [CrossRef] [PubMed]
  42. Valente, G.; Morani, F.; Nicotra, G.; Fusco, N.; Peracchio, C.; Titone, R.; Alabiso, O.; Arisio, R.; Katsaros, D.; Benedetto, C.; et al. Expression and clinical significance of the autophagy proteins BECLIN 1 and LC3 in ovarian cancer. Biomed. Res. Int. 2014, 2014, 462658. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Giatromanolaki, A.; Koukourakis, M.I.; Koutsopoulos, A.; Chloropoulou, P.; Liberis, V.; Sivridis, E. High Beclin 1 expression defines a poor prognosis in endometrial adenocarcinomas. Gynecol. Oncol. 2011, 123, 147–151. [Google Scholar] [CrossRef] [PubMed]
  44. Mermel, C.H.; Schumacher, S.E.; Hill, B.; Meyerson, M.L.; Beroukhim, R.; Getz, G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011, 12, R41. [Google Scholar] [CrossRef] [Green Version]
  45. Deneberg, S.; Grövdal, M.; Karimi, M.; Jansson, M.; Nahi, H.; Corbacioglu, A.; Gaidzik, V.; Döhner, K.; Paul, C.; Ekström, T.J.; et al. Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia 2010, 24, 932–941. [Google Scholar] [CrossRef] [Green Version]
  46. Xing, L.; Mi, W.; Zhang, Y.; Tian, S.; Zhang, Y.; Qi, R.; Lou, G.; Zhang, C. The identification of six risk genes for ovarian cancer platinum response based on global network algorithm and verification analysis. J. Cell. Mol. Med. 2020, 24, 9839–9852. [Google Scholar] [CrossRef]
  47. Chen, P.; Huhtinen, K.; Kaipio, K.; Mikkonen, P.; Aittomäki, V.; Lindell, R.; Hynninen, J.; Auranen, A.; Grénman, S.; Lehtonen, R.; et al. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy. Cancer Res. 2015, 75, 2987–2998. [Google Scholar] [CrossRef] [Green Version]
  48. Liu, Y.; Chen, C.; Xu, Z.; Scuoppo, C.; Rillahan, C.D.; Gao, J.; Spitzer, B.; Bosbach, B.; Kastenhuber, E.R.; Baslan, T.; et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature 2016, 531, 471–475. [Google Scholar] [CrossRef] [Green Version]
  49. Sedic, M.; Kuperwasser, C. BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer. Cell Cycle. 2016, 15, 621–627. [Google Scholar] [CrossRef]
  50. Zhao, Y.; Chen, S.; Gou, W.F.; Xiao, L.J.; Takano, Y.; Zheng, H.C. Aberrant Beclin 1 expression is closely linked to carcinogenesis, differentiation, progression, and prognosis of ovarian epithelial carcinoma. Tumour Biol. 2014, 35, 1955–1964. [Google Scholar] [CrossRef]
  51. Ju, L.L.; Zhao, C.Y.; Ye, K.F.; Yang, H.; Zhang, J. Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues. Eur. Rev. Med. Pharmacol Sci. 2016, 20, 1993–2003. [Google Scholar]
  52. Sokolenko, A.P.; Bizin, I.V.; Preobrazhenskaya, E.V.; Gorodnova, T.V.; Ivantsov, A.O.; Iyevleva, A.G.; Savonevich, E.L.; Kotiv, K.B.; Kuligina, E.S.; Imyanitov, E.N. Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors. Int. J. Cancer. 2020, 146, 1879–1888. [Google Scholar] [CrossRef]
  53. Gorodnova, T.; Sokolenko, A.; Ni, V.; Ivantsov, A.; Kotiv, K.; Petrik, S.; Amelina, I.; Berlev, I.; Imyanitov, E. BRCA1-associated and sporadic ovarian carcinomas: Outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy. Int. J. Gynecol Cancer. 2019, 29, 779–786. [Google Scholar] [CrossRef] [PubMed]
  54. Drost, R.M.; Jonkers, J. Preclinical mouse models for BRCA1-associated breast cancer. Br. J. Cancer 2009, 101, 1651–1657. [Google Scholar] [CrossRef] [PubMed]
  55. Vidoni, C.; Ferraresi, A.; Secomandi, E.; Vallino, L.; Dhanasekaran, D.N.; Isidoro, C. Epigenetic targeting of autophagy for cancer prevention and treatment by natural compounds. Semin. Cancer Biol. 2020, 66, 34–44. [Google Scholar] [CrossRef] [PubMed]
  56. Royston, K.J.; Udayakumar, N.; Lewis, K.; Tollefsbol, T.O. A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells. Int. J. Mol. Sci. 2017, 18, 1092. [Google Scholar] [CrossRef]
Biomedicines 09 00207 g001 550
Figure 1. The oncoprint showing the genetic alterations and mRNA expression level of BECN1, BRCA1 and TP53 in 316 ovarian serous cystadenocarcinomas from the TCGA dataset (Consortium TCGA, Nature 2011).
Figure 1. The oncoprint showing the genetic alterations and mRNA expression level of BECN1, BRCA1 and TP53 in 316 ovarian serous cystadenocarcinomas from the TCGA dataset (Consortium TCGA, Nature 2011).
Biomedicines 09 00207 g001
Biomedicines 09 00207 g002 550
Figure 2. Patients bearing a TP53-mutated tumor show better prognosis compared to TP53 wild type. (A) Overall survival for HGSOC patients according TP53 status. (B) Disease-free survival (DFS) for HGSOC patients according TP53 status. (C) Box-plot showing the distribution of BECN1 expression according TP53 status. (D) Box-plot showing the distribution of BRCA1 expression according TP53 status. (Note that for OS data were not available for 1 patient (mutated group 1 pt: 302 pt’s total n = 303 mutated pt’s) while for DFS data were missing for 56 patients (mutated group 54 pt: 249 pt’s+ wild type group 2 pt’s: 11 pt’s; total n = 316 pt’s), respectively).
Figure 2. Patients bearing a TP53-mutated tumor show better prognosis compared to TP53 wild type. (A) Overall survival for HGSOC patients according TP53 status. (B) Disease-free survival (DFS) for HGSOC patients according TP53 status. (C) Box-plot showing the distribution of BECN1 expression according TP53 status. (D) Box-plot showing the distribution of BRCA1 expression according TP53 status. (Note that for OS data were not available for 1 patient (mutated group 1 pt: 302 pt’s total n = 303 mutated pt’s) while for DFS data were missing for 56 patients (mutated group 54 pt: 249 pt’s+ wild type group 2 pt’s: 11 pt’s; total n = 316 pt’s), respectively).
Biomedicines 09 00207 g002
Biomedicines 09 00207 g003 550
Figure 3. Shallow deletion of BECN1 and BRCA1 correlates with stage IIIC and grade 3 in ovarian cancers. (A) Graph representing the distribution of BECN1 copy number variation (CNV) according to tumor stage. (B) Graph representing the distribution of BECN1 CNV according to tumor grade. (C) Graph representing the distribution of BRCA1 CNV according to tumor stage. (D) Graph representing the distribution of BRCA1 CNV according to tumor grade.
Figure 3. Shallow deletion of BECN1 and BRCA1 correlates with stage IIIC and grade 3 in ovarian cancers. (A) Graph representing the distribution of BECN1 copy number variation (CNV) according to tumor stage. (B) Graph representing the distribution of BECN1 CNV according to tumor grade. (C) Graph representing the distribution of BRCA1 CNV according to tumor stage. (D) Graph representing the distribution of BRCA1 CNV according to tumor grade.
Biomedicines 09 00207 g003
Biomedicines 09 00207 g004 550
Figure 4. Shallow deletion of BECN1 and BRCA1 with low mRNA expression is associated with better overall and disease-free survival. (A) Overall survival for HGSOC patients according to BECN1 and BRCA1 CNV. (B) Disease-free survival for HGSOC patients according to BECN1 and BRCA1 CNV. (C) Box-plot showing the distribution of BECN1 expression according to CNV. (D) Box-plot showing the distribution of BRCA1 expression according to CNV. (Note that for OS data were not available for 1 patient (diploid group - 1 pt: 49 pt’s; diploid group total n = 50 pt’s) while for DFS data were missing for 51 patients (diploid group - 16 pt’s: 34 pt’s + shallow deletion group - 35 pt’s: 205 pt’s; total n = 290 pt’s), respectively).
Figure 4. Shallow deletion of BECN1 and BRCA1 with low mRNA expression is associated with better overall and disease-free survival. (A) Overall survival for HGSOC patients according to BECN1 and BRCA1 CNV. (B) Disease-free survival for HGSOC patients according to BECN1 and BRCA1 CNV. (C) Box-plot showing the distribution of BECN1 expression according to CNV. (D) Box-plot showing the distribution of BRCA1 expression according to CNV. (Note that for OS data were not available for 1 patient (diploid group - 1 pt: 49 pt’s; diploid group total n = 50 pt’s) while for DFS data were missing for 51 patients (diploid group - 16 pt’s: 34 pt’s + shallow deletion group - 35 pt’s: 205 pt’s; total n = 290 pt’s), respectively).
Biomedicines 09 00207 g004
Biomedicines 09 00207 g005 550
Figure 5. Shallow deletion of BECN1 and BRCA1 with low mRNA expression in TP53-mutated patients is associated with better overall survival as well as disease-free survival. (A) Overall survival for HGSOC patients based on BECN1 and BRCA1 CNV. (B) Disease-free survival for HGSOC patients based on BECN1 and BRCA1 CNV. (C) Box-plot showing the distribution of BECN1 expression according to CNV. (D) Box-plot showing the distribution of BRCA1 expression according to CNV. (Note that for OS data were not available for 1 patient (diploid group 1 pt: 42 pt’s; diploid group total n = 43 pt’s) while for DFS data were missing for 49 patients (diploid group 15 pt’s: 28 pt’s + shallow deletion group 34 pt’s: 202 pt’s; total n = 279 pt’s), respectively).
Figure 5. Shallow deletion of BECN1 and BRCA1 with low mRNA expression in TP53-mutated patients is associated with better overall survival as well as disease-free survival. (A) Overall survival for HGSOC patients based on BECN1 and BRCA1 CNV. (B) Disease-free survival for HGSOC patients based on BECN1 and BRCA1 CNV. (C) Box-plot showing the distribution of BECN1 expression according to CNV. (D) Box-plot showing the distribution of BRCA1 expression according to CNV. (Note that for OS data were not available for 1 patient (diploid group 1 pt: 42 pt’s; diploid group total n = 43 pt’s) while for DFS data were missing for 49 patients (diploid group 15 pt’s: 28 pt’s + shallow deletion group 34 pt’s: 202 pt’s; total n = 279 pt’s), respectively).
Biomedicines 09 00207 g005
Biomedicines 09 00207 g006 550
Figure 6. Low expression of both BECN1 and BRCA1 independently gives better and longer overall survival as well as disease-free survival in TP53-mutated patients. (A) Box-plot showing the distribution of BECN1 expression based on expression levels (high, medium and low). (B) Overall and (C) disease-free survival for HGSOC patients based on BECN1 expression levels (high, medium and low). (D) Box-plot showing the distribution of BRCA1 expression based on expression levels (high, medium and low). (E) Overall and (F) disease-free survival analysis for HGSOC patients based on BRCA1 expression levels (high, medium and low). (Note that for BECN1 OS data were not available for 1 patient (medium group 1 pt: 106 pt’s; medium group total n = 107 pt’s) while for BECN1—DFS data were missing for 49 patients (high group 12 pt’s: 20 pt’s + medium group 20 pt’s: 87 pt’s + low group 17 pt’s: 123 pt’s; total n = 279 pt’s), respectively. For BRCA1 - OS data were not available for 1 patient (low group 1 pt: 133 pt’s; low group total n = 134 pt’s) while for BRCA1-DFS data were missing for 49 patients (high group 6 pt’s: 23 pt’s + medium group 19 pt’s: 97 pt’s + low group 24 pt’s: 110 pt’s; total n = 279 pt’s), respectively).
Figure 6. Low expression of both BECN1 and BRCA1 independently gives better and longer overall survival as well as disease-free survival in TP53-mutated patients. (A) Box-plot showing the distribution of BECN1 expression based on expression levels (high, medium and low). (B) Overall and (C) disease-free survival for HGSOC patients based on BECN1 expression levels (high, medium and low). (D) Box-plot showing the distribution of BRCA1 expression based on expression levels (high, medium and low). (E) Overall and (F) disease-free survival analysis for HGSOC patients based on BRCA1 expression levels (high, medium and low). (Note that for BECN1 OS data were not available for 1 patient (medium group 1 pt: 106 pt’s; medium group total n = 107 pt’s) while for BECN1—DFS data were missing for 49 patients (high group 12 pt’s: 20 pt’s + medium group 20 pt’s: 87 pt’s + low group 17 pt’s: 123 pt’s; total n = 279 pt’s), respectively. For BRCA1 - OS data were not available for 1 patient (low group 1 pt: 133 pt’s; low group total n = 134 pt’s) while for BRCA1-DFS data were missing for 49 patients (high group 6 pt’s: 23 pt’s + medium group 19 pt’s: 97 pt’s + low group 24 pt’s: 110 pt’s; total n = 279 pt’s), respectively).
Biomedicines 09 00207 g006
Biomedicines 09 00207 g007 550
Figure 7. Low expression of both BECN1 and BRCA1 in conjugation gives better and longer overall survival as well as disease-free survival. (A) Overall survival for HGSOC patients according to BECN1 and BRCA1 expression level (H/H, H/L, L/H and L/L). (B) Disease-free survival for HGSOC patients according to BECN1 and BRCA1 expression level (H/H, H/L, L/H and L/L). (C) Box-plot showing the distribution of BECN1 according to expression level (high and low). (D) Box-plot showing the distribution of BRCA1 according to expression level (high and low). (Note that for OS data were not available for 1 patient (L/L group 1 pt: 225 pt’s; L/L group total n = 226 pt’s) while for DFS data were missing for 49 patients (H/H group 3 pt’s: 5 + H/L group 10 pt’s: 15 pt’s + L/H group 6 pt’s: 18 pt’s + L/L group 34 pt’s: 192; total n = 279 pt’s), respectively).
Figure 7. Low expression of both BECN1 and BRCA1 in conjugation gives better and longer overall survival as well as disease-free survival. (A) Overall survival for HGSOC patients according to BECN1 and BRCA1 expression level (H/H, H/L, L/H and L/L). (B) Disease-free survival for HGSOC patients according to BECN1 and BRCA1 expression level (H/H, H/L, L/H and L/L). (C) Box-plot showing the distribution of BECN1 according to expression level (high and low). (D) Box-plot showing the distribution of BRCA1 according to expression level (high and low). (Note that for OS data were not available for 1 patient (L/L group 1 pt: 225 pt’s; L/L group total n = 226 pt’s) while for DFS data were missing for 49 patients (H/H group 3 pt’s: 5 + H/L group 10 pt’s: 15 pt’s + L/H group 6 pt’s: 18 pt’s + L/L group 34 pt’s: 192; total n = 279 pt’s), respectively).
Biomedicines 09 00207 g007
Biomedicines 09 00207 g008 550
Figure 8. Concurrent low expression of BECN1 and BRCA1 correlates with platinum sensitivity. (A) Platinum sensitivity based on CNV of BECN1 and BRCA1 in TP53-mutated patients. (B) Platinum sensitivity based on BECN1 mRNA expression. (C) Platinum sensitivity based on BRCA1 mRNA expression. All patients underwent primary cytoreductive surgery, followed by adjuvant platinum-based chemotherapy as first-line treatment. Platinum sensitivity: the time from adjuvant platinum-based treatment to cancer relapse (platinum-free interval, PFI) was >6 months. Late Resistance: resistance occurs after a 6-month-period. Too-early Resistance: resistance occurs as soon as treatment started (within 6 months).
Figure 8. Concurrent low expression of BECN1 and BRCA1 correlates with platinum sensitivity. (A) Platinum sensitivity based on CNV of BECN1 and BRCA1 in TP53-mutated patients. (B) Platinum sensitivity based on BECN1 mRNA expression. (C) Platinum sensitivity based on BRCA1 mRNA expression. All patients underwent primary cytoreductive surgery, followed by adjuvant platinum-based chemotherapy as first-line treatment. Platinum sensitivity: the time from adjuvant platinum-based treatment to cancer relapse (platinum-free interval, PFI) was >6 months. Late Resistance: resistance occurs after a 6-month-period. Too-early Resistance: resistance occurs as soon as treatment started (within 6 months).
Biomedicines 09 00207 g008
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Salwa, A.; Ferraresi, A.; Chinthakindi, M.; Vallino, L.; Vidoni, C.; Dhanasekaran, D.N.; Isidoro, C. BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis. Biomedicines 2021, 9, 207. https://doi.org/10.3390/biomedicines9020207

AMA Style

Salwa A, Ferraresi A, Chinthakindi M, Vallino L, Vidoni C, Dhanasekaran DN, Isidoro C. BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis. Biomedicines. 2021; 9(2):207. https://doi.org/10.3390/biomedicines9020207

Chicago/Turabian Style

Salwa, Amreen, Alessandra Ferraresi, Menaka Chinthakindi, Letizia Vallino, Chiara Vidoni, Danny N. Dhanasekaran, and Ciro Isidoro. 2021. "BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis" Biomedicines 9, no. 2: 207. https://doi.org/10.3390/biomedicines9020207

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop